6-K 1 a4946f.htm DIRECTOR/PDMR SHAREHOLDING a4946f
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May 2026
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number 
Description
99.1
22 May 2026 - Director/PDMR Shareholding
 
 
 
 
99.1
 
 
 
​Haleon plc: Director/PDMR Shareholding 
​ 
​22 May 2026: Haleon plc (the “Company” or “Haleon”) (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
 
On 21 May 2026, the Company was notified of the following transactions as detailed below.
 
1
 
Details of the issuer, emission allowance market participant
 
a)
 
Name  
 
Haleon plc
b)
LEI
 
549300PSB3WWEODCUP19 
2
 
Reason for the notification  
 
a)
 
Position/status  
 
Chief Financial Officer
b)
 
Initial notification /Amendment  
 
Initial Notification 
3
 
Details of the person discharging managerial responsibilities / person closely associated (“PCA”) 
a)
 
PDMR/PCA
 
PDMR
b)
 
Name  
 
Dawn Allen
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)
 
Description of Instrument
 
Identification code  
 
Share
 
GB00BMX86B70   
 
b)
 
Nature of the transaction  
 
Acquisition of Ordinary Shares as a result of dividend reinvestment
 
c)
 Currency, Price(s) and volume(s)  
Price(s) 
 
Volume(s) 
£3.4022
 
2,596.07411
d)
 
Aggregated information  
 
- Aggregated volume 
 
- Price 
 
 N/A
 
e)
 
Date of the transaction  
 
19 May 2026
 
f)
 
Place of the transaction  
 
London Stock Exchange (XLON) 
 
 
1
 
Details of the issuer, emission allowance market participant
 
a)
 
Name  
 
Haleon plc
b)
 
LEI  
 
549300PSB3WWEODCUP19
2
 
Reason for the notification  
 
a)
 
Position/status  
 
Chief Executive Officer
b)
 
Initial notification /Amendment  
 
Initial Notification 
3
 
Details of the person discharging managerial responsibilities / person closely associated (“PCA”) 
 
a)
 
PDMR/PCA
PDMR 
b)
 
Name
 
Brian McNamara
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)
 
Description of Instrument  
 
Identification code  
Share
 
GB00BMX86B70   
 
b)
 
Nature of the transaction  
 
Acquisition of Ordinary Shares as a result of dividend reinvestment
 
c)
 
 
Currency, Price(s) and volume(s)  
 
Price(s) 
 
Volume(s) 
£3.4022
 
24,891.04716
d)
 
Aggregated information  
 
- Aggregated volume 
 
- Price 
 
 N/A
 
e)
 
Date of the transaction  
 
19 May 2026
 
f)
 
Place of the transaction  
 
London Stock Exchange (XLON) 
4
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
 
a)
 
Description of Instrument
 
Identification code  
Share
 
US4055521003  
 
b)
 
Nature of the transaction  
 
Acquisition of ADSs as a result of dividend reinvestment
 
c)
Currency, Price(s) and volume(s)  
 
Price(s) 
 
 Volume(s) 
$9.2446
 
4,414.93735
d)
 
Aggregated information  
 
- Aggregated volume 
 
- Price 
 
 N/A
 
e)
 
Date of the transaction  
 
19 May 2026
f)
 
Place of the transaction  
 
New York Stock Exchange (XNYS)
 
 
Amanda Mellor
Company Secretary
 
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.
 
For more information, please visit www.haleon.com. 
 

 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: May 22, 2026
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary